{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:45:18Z","timestamp":1794491118594,"version":"4.9.1"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Chinese Medicine Education Association","award":["2023WSJSPGZXKT-04"],"award-info":[{"award-number":["2023WSJSPGZXKT-04"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:p>This study evaluates the efficacy, safety, and economics of galantamine in the treatment of Alzheimer disease (AD) patients, and to provide evidence-based reference for optimizing drug selection, dosing strategies, and reimbursement policies in clinical practice. We used galantamine, systematic review, cost, and their synonym as keywords. The PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Weipu, Wanfang database, and Health Technology Assessment organization websites were searched to retrieve studies regarding galantamine for the treatment of AD from database creation to September 20, 2023. We extracted information and pooled the results of the studies for qualitative analyses instead of quantitative meta-analysis. This study incorporated 39 reports. Regarding effectiveness, galantamine significantly improved cognitive function, living capacity, mental behavior, and global functioning of the AD patients compared with the placebo. However, based on available data, it was not possible to infer whether galantamine was more effective than the other acetylcholinesterase inhibitor drugs. AD patients treated with galantamine showed a higher incidence of adverse gastrointestinal effects compared to those treated with placebo. Galantamine showed a higher incidence of adverse gastrointestinal effects than donepezil but a lower rate than rivastigmine. Regarding economics, compared with the placebo and non-pharmacological treatments, galantamine prolonged the duration of full-time care and in some cases even reduced the overall cost of galantamine use. Galantamine showed good efficacy, cost-effectiveness, and mild adverse effects in the treatment of patients with AD by prolonging the duration of full-time care and saving the cost compared with the placebo and non-pharmacological.<\/jats:p>","DOI":"10.1097\/md.0000000000042744","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T17:01:19Z","timestamp":1749488479000},"page":"e42744","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Rapid health technology assessment of galantamine for the treatment of Alzheimer\u2019s disease: A review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5050-0225","authenticated-orcid":false,"given":"Bingke","family":"Xing","sequence":"first","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China"},{"name":"The Research Center of National Drug Policy and Ecosystem, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingran","family":"Yang","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China"},{"name":"The Research Center of National Drug Policy and Ecosystem, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Hua","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3055-2159","authenticated-orcid":false,"given":"Rong","family":"Jiang","sequence":"additional","affiliation":[{"name":"School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, Jiangsu, China"},{"name":"The Research Center of National Drug Policy and Ecosystem, Nanjing, Jiangsu, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"101448","DOI":"10.1016\/j.arr.2021.101448","article-title":"Effectiveness of caregiver non-pharmacological interventions for behavioural and psychological symptoms of dementia: an updated meta-analysis.","volume":"71","author":"Meng","year":"2021","journal-title":"Ageing Res Rev"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jalz.2017.12.006","article-title":"The cost of Alzheimer\u2019s disease in China and re-estimation of costs worldwide.","volume":"14","author":"Jia","year":"2018","journal-title":"Alzheimers Dement"},{"key":"R3-20250609","first-page":"5906","article-title":"Progress in the study of the pathogenesis of Alzheimer\u2019s disease.","volume":"34","author":"Xianhui","year":"2014","journal-title":"Chin J Gerontol"},{"key":"R4-20250609","first-page":"1939","article-title":"Pathogenesis and new therapeutic drugs of Alzheimer disease.","volume":"55","author":"Qiqiong","year":"2020","journal-title":"Chin Pharm J"},{"key":"R5-20250609","first-page":"269","article-title":"Chinese guideline for the diagnosis and treatment of Alzheimer\u2019s disease dementia.","volume":"40","author":"Jinzhou","year":"2021","journal-title":"Chin J Geriatr"},{"key":"R6-20250609","first-page":"421","article-title":"Chinese expert consensus on the diagnosis and treatment of mild cognitive impairment due to Alzheimer\u2032s disease 2021.","volume":"55","year":"2022","journal-title":"Chin J Neurol"},{"key":"R7-20250609","first-page":"110","article-title":"Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer\u2019s disease and other dementias.","volume":"15","author":"Rabins","year":"2017","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"R8-20250609","first-page":"45","article-title":"Review of galantamine in the treatment of Alzheimer\u2019s disease.","volume":"01","author":"Cong","year":"2008","journal-title":"Pharm Clin Res"},{"key":"R9-20250609","first-page":"85","article-title":"Advances in the synthesis pathways of galanthamine.","volume":"36","author":"Ribao","year":"2016","journal-title":"J Hunan Univ Chin Med"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations.","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"R12-20250609","article-title":"Inahta briefs, checklists & impact framework."},{"key":"R13-20250609","first-page":"557","article-title":"Efficacy and safety of cholinesterase inhibitors in Alzheimer\u2019s disease: a meta-analysis.","volume":"169","author":"Lanct\u00f4t","year":"2003","journal-title":"CMAJ"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000079388","article-title":"Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.","volume":"18","author":"Kurz","year":"2004","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/hup.676","article-title":"A comparison of donepezil and galantamine in the treatment of cognitive symptoms of Alzheimer\u2019s disease: a meta-analysis.","volume":"20","author":"Harry","year":"2005","journal-title":"Hum Psychopharmacol"},{"key":"R16-20250609","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/gps.1402","article-title":"A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer\u2019s disease.","volume":"21","author":"Takeda","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"R17-20250609","first-page":"CD001747","article-title":"Galantamine for Alzheimer\u2019s disease and mild cognitive impairment.","volume":"2006","author":"Loy","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"R18-20250609","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer\u2019s disease: a systematic review and meta-analysis.","volume":"3","author":"Hansen","year":"2008","journal-title":"Clin Interv Aging"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2147\/CIA.S4250","article-title":"Impact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer\u2019s disease: a meta-analysis.","volume":"3","author":"Campbell","year":"2008","journal-title":"Clin Interv Aging"},{"key":"R20-20250609","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1041610209990354","article-title":"Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.","volume":"21","author":"Rodda","year":"2009","journal-title":"Int Psychogeriatr"},{"key":"R21-20250609","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000255578","article-title":"Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer\u2019s disease: systematic review of the \u2018real-world\u2019 evidence.","volume":"28","author":"Lockhart","year":"2009","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R22-20250609","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/156720511795256044","article-title":"Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer\u2019s disease.","volume":"8","author":"Kavanagh","year":"2011","journal-title":"Curr Alzheimer Res"},{"key":"R24-20250609","first-page":"66","article-title":"Meta analysis on the effect of galantamine in the treatment of Alzheimer\u2019s disease.","volume":"35","author":"Sisi","year":"2014","journal-title":"Lasernal"},{"key":"R25-20250609","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00702-014-1358-0","article-title":"Efficacy and safety of galantamine treatment for patients with Alzheimer\u2019s disease: a meta-analysis of randomized controlled trials.","volume":"122","author":"Jiang","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"R26-20250609","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/gps.4405","article-title":"The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer\u2019s disease: a Bayesian network meta-analysis.","volume":"31","author":"Kobayashi","year":"2016","journal-title":"Int J Geriatr Psychiatry"},{"key":"R27-20250609","first-page":"1735","article-title":"Effect of cholinesterase Inhibitorson on cognition of patients with mild to moderate Alzheimer\u2019s disease: a meta-analysis.","volume":"20","author":"Qian","year":"2017","journal-title":"Chin Gen Pract"},{"key":"R28-20250609","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jgs.15069","article-title":"Comparative effectiveness and safety of cognitive enhancers for treating Alzheimer\u2019s disease: systematic review and network meta analysis.","volume":"66","author":"Tricco","year":"2018","journal-title":"J Am Geriatr Soc"},{"key":"R29-20250609","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13195-018-0457-9","article-title":"Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer\u2019s disease: a network meta-analysis of 41 randomized controlled trials.","volume":"10","author":"Dou","year":"2018","journal-title":"Alzheimers Res Ther"},{"key":"R30-20250609","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.2147\/CIA.S184968","article-title":"Identification of the optimal cognitive drugs among Alzheimer\u2019s disease: a Bayesian meta-analytic review.","volume":"13","author":"Liang","year":"2018","journal-title":"Clin Interv Aging"},{"key":"R31-20250609","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s40266-019-00648-x","article-title":"Ginkgo biloba extract (EGb761), cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer\u2019s disease: a network meta-analysis.","volume":"36","author":"Thancharoen","year":"2019","journal-title":"Drugs Aging"},{"key":"R32-20250609","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3389\/fnins.2019.00472","article-title":"Meta-analysis of randomized controlled trials on the efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer\u2019s disease.","volume":"13","author":"Li","year":"2019","journal-title":"Front Neurosci"},{"key":"R33-20250609","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fphar.2020.00778","article-title":"Different doses of pharmacological treatments for mild to moderate Alzheimer\u2019s disease: a Bayesian network meta-analysis.","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Pharmacol"},{"key":"R34-20250609","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1212\/WNL.57.6.972","article-title":"Assessment of health economics in Alzheimer\u2019s disease (AHEAD): galantamine treatment in Canada.","volume":"57","author":"Getsios","year":"2001","journal-title":"Neurology"},{"key":"R35-20250609","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2165\/00019053-200220090-00006","article-title":"Assessment of health economics in Alzheimer\u2019s disease (AHEAD): treatment with galantamine in Sweden.","volume":"20","author":"Garfield","year":"2002","journal-title":"PharmacoEcon"},{"key":"R36-20250609","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000064929","article-title":"Assessment of health economics in Alzheimer\u2019s disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer\u2019s disease in the Netherlands.","volume":"14","author":"Caro","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"key":"R37-20250609","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/gps.919","article-title":"Assessment of health economics in Alzheimer\u2019s disease (AHEAD): treatment with galantamine in the UK.","volume":"18","author":"Ward","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"key":"R38-20250609","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/S0149-2918(03)80171-6","article-title":"Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer\u2019s disease in the United States.","volume":"25","author":"Migliaccio-Walle","year":"2003","journal-title":"Clin Ther"},{"key":"R39-20250609","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2318-3-6","article-title":"Rational choice of cholinesterase inhibitor for the treatment of Alzheimer\u2019s disease in Canada: a comparative economic analysis.","volume":"3","author":"Caro","year":"2003","journal-title":"BMC Geriatr"},{"key":"R40-20250609","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2165\/00002512-200421100-00005","article-title":"Assessing the health and economic impact of galantamine treatment in patients with Alzheimer\u2019s disease in the health care systems of different countries.","volume":"21","author":"Caro","year":"2004","journal-title":"Drugs Aging"},{"key":"R41-20250609","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2165\/00019053-200523120-00010","article-title":"Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer\u2019s disease.","volume":"23","author":"Green","year":"2005","journal-title":"PharmacoEcon"},{"key":"R42-20250609","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3346\/jkms.2008.23.1.10","article-title":"Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer\u2019s disease in a Korean population: a 52-week prospective study.","volume":"23","author":"Suh","year":"2008","journal-title":"J Korean Med Sci"},{"issue":"Suppl 3","key":"R43-20250609","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1111\/j.1524-4733.2009.00627.x","article-title":"Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer\u2019s disease in Korea.","volume":"12","author":"Suh","year":"2009","journal-title":"Value Health"},{"key":"R44-20250609","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3111\/13696998.2010.528101","article-title":"Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer\u2019s disease in Germany.","volume":"13","author":"Guo","year":"2010","journal-title":"J Med Econ"},{"key":"R45-20250609","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3111\/13696998.2012.680554","article-title":"The economic impact of galantamine vs placebo: an analysis based on functional capacity in a Swedish cohort study.","volume":"15","author":"Wimo","year":"2012","journal-title":"J Med Econ"},{"key":"R46-20250609","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jval.2020.01.010","article-title":"Application of discrete-event simulation in health technology assessment: a cost-effectiveness analysis of Alzheimer\u2019s disease treatment using real-world evidence in Thailand.","volume":"23","author":"Kongpakwattana","year":"2020","journal-title":"Value Health"},{"key":"R47-20250609","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3233\/ADR-210307","article-title":"Comparative value of cholinesterase inhibitors and memantine in persons with moderate-to-severe Alzheimer\u2019s disease in the United States: a cost-effectiveness analysis.","volume":"5","author":"Yunusa","year":"2021","journal-title":"J Alzheimers Dis Rep"},{"key":"R48-20250609","first-page":"1","article-title":"Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer\u2019s disease: a rapid and systematic review.","volume":"5","author":"Clegg","year":"2001","journal-title":"Health Technol Assess"},{"key":"R50-20250609","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta16210","article-title":"The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease (review of Technology Appraisal No. 111): a systematic review and economic model.","volume":"16","author":"Bond","year":"2012","journal-title":"Health Technol Assess"},{"key":"R51-20250609","article-title":"Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer\u2019s disease;","year":"2018"},{"key":"R53-20250609","doi-asserted-by":"crossref","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","article-title":"Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study.","volume":"5","author":"Jia","year":"2020","journal-title":"Lancet Public Health"},{"key":"R54-20250609","first-page":"289","article-title":"Alzheimer disease in China (2015-2050) estimated using the 1% population sampling survey in 2015.","volume":"2","author":"Yingquan","year":"2019","journal-title":"Chin J Alzheimers Dis Relat Disord"},{"key":"R55-20250609","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrn2168","article-title":"Intracellular amyloid-\u03b2 in Alzheimer\u2019s disease.","volume":"8","author":"LaFerla","year":"2007","journal-title":"Nat Rev Neurosci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042744","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T17:01:32Z","timestamp":1749488492000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":52,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042744","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}